leisure time -WSS

leisure time

author：fashion 2025-09-06 04:12:56 - browse：84423

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： White House pharmacy plagued with problems, investigation finds

hotspot

WSS

Philips to halt sales of sleep apnea machines in U.S.

Reconstructing family trees of blood cells may help predict disease

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Review: 'Barbie' will hit you like a shot in the heart

Court strikes down limits on filming of police in Arizona

hotspot

leisure time

explore

Affirmative action in medical school literally saved lives

Russian special forces kill a gunman who broke into a private house near Moscow

New air purifier tech could be key to improving indoor air quality

How generative AI ratchets up security threats for health systems

Duchenne breakthrough therapy leaves behind pioneering families

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Bright Health sells Medicare Advantage business to Molina

White House pharmacy plagued with problems, investigation finds

Wildfire smoke exposes gaps in outdoor worker protections

Merck CEO won’t testify in Senate, citing no expertise in drug prices

leisure time

Pancreatic cancer early detection could be helped by AI

Readout Newsletter: The latest on Novavax, Merck, Bluebird

New rules on organ donation and transplantation 'will bring chaos'

Venture capital firm's plans to take over Akron hospital face hurdles

What to know about Saharan dust affecting the US and how it can affect health

Philips to halt sales of sleep apnea machines in U.S.

leisure time

hotspot

Wikipedia

explore